Retrospective analysis of treatments with recombinant FSH and recombinant LH versus human menopausal gonadotropin in women with reduced ovarian reserve.

Purposes: The aim of this study is to determine whether a clinical advantage is gained with use of LH in combination with FSH or as a component of human menopausal gonadotropin (hMG) to achieve optimal ovarian stimulation.

Methods: In this study, we compared retrospectively two regimens, r-FSH/r-LH and hMG, for the treatment of women with reduced ovarian reserve, identified as subjects with antral follicle count (AFC) < 11 and AMH ≤ 1.1 ng/ml.

Comparison of the obstetric and perinatal outcomes of children conceived from in vitro or in vivo matured oocytes in in vitro maturation treatments with births from conventional ICSI cycles.

Study Question: Are the obstetric and perinatal outcomes of deliveries following in vitro maturation (IVM) cycles different from births generated from controlled ovarian stimulation (COS) cycles?

Summary Answer: The obstetric and perinatal outcomes of births from IVM cycles are comparable with those of ICSI treatments, including the incidence of major and minor abnormalities.

What Is Known Already: Only few and numerically small reports on the health of IVM children are currently available.

Study Design, Size And Duration: Retrospective cohort study involving 196 babies born from IVM cycles carried out with different priming regimens.

Cleavage kinetics analysis of human embryos predicts development to blastocyst and implantation.

Cleavage kinetics of human embryos is indicative of ability to develop to blastocyst and implant. Recent advances in time-lapse microscopy have opened new and important research opportunities. In this study involving infertile couples requiring standard IVF/intracytoplasmic sperm injection treatment, zygotes were cultured by integrated embryo-culture time-lapse microscopy to analyse cleavage times from the 2- to the 8-cell stages in relation to the ability to develop to blastocyst, expand and implant.

Anti-mullerian hormone as a predictive marker for the selection of women for oocyte in vitro maturation treatment.

Purpose: In oocyte in-vitro maturation (IVM) treatments, the chances to achieve a pregnancy are critically dependent on the retrieval of a suitable number of oocytes. In this study, we assessed the ability of circulating levels of anti-mullerian hormone (AMH) to identify normo-ovulatory women suitable for IVM treatment on the basis of the number of retrieved oocytes.

Method: Serum AMH was quantified in normo-ovulatory women younger than 39 years undergoing IVM treatment.

Outcome of cycles of oocyte in vitro maturation requiring testicular sperm extraction for nonobstructive azoospermia.

Objective: To assess the applicability of oocyte IVM in case of nonobstructive azoospermia (NOA).

Design: Case series.

Setting: Private IVF unit.